Cancer of Unknown Primary Site Active Not Recruiting Phase 2 Trials for Vismodegib (DB08828)

Indication	Status	Phase
DBCOND0089665 (Cancer of Unknown Primary Site)	Active Not Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03498521	A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site	Treatment	Alectinib (DB11363) Atezolizumab (DB11595) Bevacizumab (DB00112) Carboplatin (DB00958) Cisplatin (DB00515) Cobimetinib (DB05239) Entrectinib (DB11986) Erlotinib (DB00530) Gemcitabine (DB00441) Ipatasertib (DB11743) Ivosidenib (DB14568) Olaparib (DB09074) Paclitaxel (DB01229) Pemigatinib (DB15102) Pertuzumab (DB06366) Trastuzumab (DB00072) Vemurafenib (DB08881) Vismodegib (DB08828)